Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
The latest from Redeye about Scandinavian Life Science and Technology companies

Senzime

Direct sales model in Germany

Research Note 2021-01-15
SEZI

Alzinova

Another external validation

Research Note 2021-01-15
ALZ

PiezoMotor Uppsala

Progress in cell phone business project

Research Note 2021-01-15
PIEZO

Flexion Mobile

The Growth Journey Continues

Research Note 2021-01-14
FLEXM

Xspray Pharma

Brief Comment on Today’s Results

Research Note 2021-01-14
XSPRAY

Sensys Gatso Group

Quick Comment Regarding the Investigation

Research Note 2021-01-14
SENS

Hexatronic Group

Q4’20: Solid beat in preliminary numbers

Research Note 2021-01-14
HTRO

Acarix

Promising preliminary results

Research Note 2021-01-14
ACARIX

InDex Pharmaceuticals

Initial take on financing terms

Research Note 2021-01-14
INDEX

Nanexa

Focus on Lenalidomide in New In-House Project ”NEX 20”

Research Note 2021-01-14
NANEXA

BioArctic

Validation of the amyloid-beta hypothesis

Research Note 2021-01-14
BIOA B

Enlabs

In the Wait for the Raise

Research Note 2021-01-14
NLAB

Hansa Biopharma

2021 – första året på marknad

Research Update 2021-01-14
HNSA

Smart Eye

Another Massive Downplayed Contract

Research Note 2021-01-13
SEYE

Medivir

Intervju med vd Yilmaz Mahshid (video)

Research Interview 2021-01-13
MVIR B

Nanexa

First Part of Investment Agreement Completed

Research Note 2021-01-13
NANEXA
Research
  • Research Interview 2021-01-19

    Nanexa: Intervju med vd David Westberg (video)

    Fredrik Thor
  • Research Interview 2021-01-19

    Media and Games Invest: Interview regarding the biggest acquisition yet

    Tomas Otterbeck
  • Research Note 2021-01-19

    Calliditas Therapeutics: Our Comment on Phase I Data with Setanaxib

    Ludvig Svensson
  • Research Note 2021-01-18

    Better Collective: Betting and Regulatory Tailwind

    Jonas Amnesten
  • Research Note 2021-01-18

    Fortnox CMD: Utilizing and strengthening its leading position in Sweden

    Fredrik Nilsson
  • Research Interview 2021-01-15

    Xspray Pharma: Intervju med vd Per Andersson (video)

    Ludvig Svensson
Read all
Community
  • 2021-01-18

    PolarCool - Global expansion - BrainCool satsar med FDA/USA

    markin
  • 2021-01-17

    Bubblan ingen vill spräcka

    labull
  • 2021-01-17

    Gabather, bolaget som flyger långt under radarn?

    CanNeverStop(CNS)
  • 2021-01-17

    Go-to-market med Paypal

    payme2
  • 2021-01-15

    Framtidens "gröna" supermaterial från Svenska Aerogel - Quartzene!

    eatsleepmakemoneyrepeat
  • 2021-01-14

    Divio technologies - Break-even närmar sig

    Perspez
Read all
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Terms and conditions - Advisory (Swedish)
  • Terms and conditions - Advisory (English)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2021